iifl-logo
  • testing
  • |

iifl-logo

Dr Reddys Laboratories Ltd Board Meeting

1,348.8
(2.25%)
Jun 10, 2025|12:00:00 AM

Dr Reddys Labs CORPORATE ACTIONS

30/06/2024calendar-icon
30/06/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting9 May 202521 Mar 2025
Audited Results & Dividend Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 ,inter alia, to consider and approve audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending March 31, 2025 and to recommend final dividend, if any, for the financial year 2024-25 Outcome of Board Meeting Audited Financial results for the quarter and year ended March 31, 2025 (As Per BSE Announcement Dated on: 09/05/2025)
Board Meeting23 Jan 202523 Dec 2024
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2024. Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company, at its meeting held on January 23, 2025, has inter alia approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024. (As Per BSE Announcement Dated on: 23/01/2025)
Board Meeting5 Nov 202422 Sep 2024
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2024 Board of Directors of the Company at its meeting held on November 5, 2024, has inter alia approved the following: 1. Financial results a. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter and halfyear ended September 30, 2024, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); b. Press Release on Unaudited Financial Results of the Company for the above period. c. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter and halfyear ended September 30, 2024, as per Indian Accounting Standards. d. Unaudited Standalone Financial Results of the Company for the quarter and half-year ended September 30, 2024, as per Indian Accounting Standards. Pursuant to Regulation 33 of the SEBI Listing Regulations, the Limited Review Reports of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results as mentioned at serial nos. (c) & (d) are also enclosed. 2. Investment in step-down wholly owned subsidiary company Approval of the fund infusion by way of investment in equity shares of Dr. Reddys Laboratories LLC, Russia, a step-down wholly-owned subsidiary, upto an amount of Rs.600 Crores. The fund will be used for working capital requirements. The requisite details as required under SEBI Listing Regulations, read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, will be disclosed to the stock exchange(s) after approval of the Board of the said step-down wholly-owned subsidiary. (As Per BSE Announcement Dated on 05.11.2024)
Board Meeting27 Jul 202421 Jun 2024
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ending on June 30 2024 Outcome of Board Meeting (As Per BSE Announcement dated on 27.07.2024)

Dr Reddys Labs: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

testing
  • testing
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

testing
  • testing
  • testing

ATTENTION INVESTOR

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.